| PRODUCT | DETAILS |
|---|---|
| Fruzaqla | — |
| Surufatinib | — |
| Savolitinib | — |
| Fruquintinib | — |
Hong Kong-based oncology company with NYSE (HCM) and HKEX (13.HK) listings. Fruzaqla (fruquintinib) became the first China-originated drug approved by FDA for colorectal cancer in 2023, a major milestone. Partnered with Takeda for global fruquintinib rights. Focuses on kinase inhibitors and immuno-oncology.